الصفحة الرئيسية>>Signaling Pathways>> PROTAC>> PROTAC and Building Blocks>>KB02-SLF

KB02-SLF

رقم الكتالوجGC62186

KB02-SLF عبارة عن مطهر نووي FKBP12 قائم على PROTAC (غراء جزيئي)يعزز KB02-SLF تدهور FKBP12 النووي عن طريق تعديل DCAF16 (E3 ligase) بشكل تساهمي ويمكنه تحسين متانة تدهور البروتين في النظم البيولوجيةيربط SLF ubiquitin E3 ligase KB02 عبر رابط لتشكيل KB02-SLF

Products are for research use only. Not for human use. We do not sell to patients.

KB02-SLF التركيب الكيميائي

Cas No.: 2384184-40-9

الحجم السعر المخزون الكميّة
1 mg
1035٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

KB02-SLF is a PROTAC-based nuclear FKBP12 degrader (molecular glue). KB02-SLF promotes nuclear FKBP12 degradation by covalently modifying DCAF16 (E3 ligase) and can improve the durability of protein degradation in biological systems. SLF binds ubiquitin E3 ligase ligand KB02 via a linker to form KB02-SLF[1].

KB02-SLF (2 µM; 4-72 hours; HEK293T cells) treatment promotes a substantial reduction in nuclear FKBP12 that is sustained across a 4-72 h time frame[1].Cell imaging studies confirms the selective loss of nuclear-localized FKBP12 in KB02-SLF-treated cells. KB02-SLF promotes the loss of FKBP12_NLS across a concentration of ~0.5-5µM, but shows varied reductions in activity at higher concentrations. The degradation of FKBP12_NLS induced by KB02-SLF is mediated by DCAF16[1].

[1]. Zhang X, et al. Electrophilic PROTACs that degrade nuclear proteins by engaging DCAF16. Nat Chem Biol. 2019 Jul;15(7):737-746.

مراجعات

Review for KB02-SLF

Average Rating: 5 ★★★★★ (Based on Reviews and 29 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for KB02-SLF

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.